{"title":"数字病理学使乳腺癌HER2/neu检测精益管理","authors":"Aishwarya Sharma , Prarthna Shah , Manali Ranade , Trupti Pai , Ayushi Sahay , Asawari Patil , Tanuja Shet , Heena Gupta , Devika Chauhan , Puneet Somal , Sankalp Sancheti , Sangeeta Desai","doi":"10.1016/j.jpi.2025.100515","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Invasive breast carcinomas with an equivocal result of HER2/neu on immunohistochemistry (IHC) are reflex tested by fluorescent in situ hybridisation (FISH). Molecular testing is often not available in rural laboratories, from where it is routinely outsourced to central laboratories. Histopathology review (HPR) and IHC analysis of the tissue sample is thus repeated at the central laboratory before molecular testing which increases the turnaround time (TAT) and cost incurred by both the patient and the hospital. We aimed to assess the reduction in TAT and the cost effectiveness after introducing Digital Pathology (DP).</div></div><div><h3>Methods</h3><div>The tumours with equivocal HER2/neu results were outsourced for FISH from HBCH, Sangrur (rural laboratory) to Molecular Pathology Laboratory, TMH, Mumbai (central laboratory). The Haematoxylin-Eosin (HE) and IHC slides of 47 cases were virtually shared after scanning by Philips SG 60 digital slide scanner. Paraffin blocks of these cases were sent for FISH testing only. TAT of these prospectively shared cases were compared with a retrospective cohort in which virtual slides were not available. The cost benefits were also assessed.</div></div><div><h3>Results</h3><div>With the availability of DP, we were able to obviate repeat IHC testing. We were able to achieve a 43.9 % reduction in the TAT (15.65 days to 8.775 days). We also achieved a 30 % reduction in cost.</div></div><div><h3>Conclusion</h3><div>This is a prototype study highlighting the utility of DP in the lean management of HER2/neu testing. The integration of DP in the referral process reduces the TAT and expenditure optimizing resource utilisation.</div></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"19 ","pages":"Article 100515"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Digital pathology enabling lean management of HER2/neu testing in breast Cancer\",\"authors\":\"Aishwarya Sharma , Prarthna Shah , Manali Ranade , Trupti Pai , Ayushi Sahay , Asawari Patil , Tanuja Shet , Heena Gupta , Devika Chauhan , Puneet Somal , Sankalp Sancheti , Sangeeta Desai\",\"doi\":\"10.1016/j.jpi.2025.100515\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Invasive breast carcinomas with an equivocal result of HER2/neu on immunohistochemistry (IHC) are reflex tested by fluorescent in situ hybridisation (FISH). Molecular testing is often not available in rural laboratories, from where it is routinely outsourced to central laboratories. Histopathology review (HPR) and IHC analysis of the tissue sample is thus repeated at the central laboratory before molecular testing which increases the turnaround time (TAT) and cost incurred by both the patient and the hospital. We aimed to assess the reduction in TAT and the cost effectiveness after introducing Digital Pathology (DP).</div></div><div><h3>Methods</h3><div>The tumours with equivocal HER2/neu results were outsourced for FISH from HBCH, Sangrur (rural laboratory) to Molecular Pathology Laboratory, TMH, Mumbai (central laboratory). The Haematoxylin-Eosin (HE) and IHC slides of 47 cases were virtually shared after scanning by Philips SG 60 digital slide scanner. Paraffin blocks of these cases were sent for FISH testing only. TAT of these prospectively shared cases were compared with a retrospective cohort in which virtual slides were not available. The cost benefits were also assessed.</div></div><div><h3>Results</h3><div>With the availability of DP, we were able to obviate repeat IHC testing. We were able to achieve a 43.9 % reduction in the TAT (15.65 days to 8.775 days). We also achieved a 30 % reduction in cost.</div></div><div><h3>Conclusion</h3><div>This is a prototype study highlighting the utility of DP in the lean management of HER2/neu testing. The integration of DP in the referral process reduces the TAT and expenditure optimizing resource utilisation.</div></div>\",\"PeriodicalId\":37769,\"journal\":{\"name\":\"Journal of Pathology Informatics\",\"volume\":\"19 \",\"pages\":\"Article 100515\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pathology Informatics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2153353925001014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pathology Informatics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2153353925001014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Digital pathology enabling lean management of HER2/neu testing in breast Cancer
Introduction
Invasive breast carcinomas with an equivocal result of HER2/neu on immunohistochemistry (IHC) are reflex tested by fluorescent in situ hybridisation (FISH). Molecular testing is often not available in rural laboratories, from where it is routinely outsourced to central laboratories. Histopathology review (HPR) and IHC analysis of the tissue sample is thus repeated at the central laboratory before molecular testing which increases the turnaround time (TAT) and cost incurred by both the patient and the hospital. We aimed to assess the reduction in TAT and the cost effectiveness after introducing Digital Pathology (DP).
Methods
The tumours with equivocal HER2/neu results were outsourced for FISH from HBCH, Sangrur (rural laboratory) to Molecular Pathology Laboratory, TMH, Mumbai (central laboratory). The Haematoxylin-Eosin (HE) and IHC slides of 47 cases were virtually shared after scanning by Philips SG 60 digital slide scanner. Paraffin blocks of these cases were sent for FISH testing only. TAT of these prospectively shared cases were compared with a retrospective cohort in which virtual slides were not available. The cost benefits were also assessed.
Results
With the availability of DP, we were able to obviate repeat IHC testing. We were able to achieve a 43.9 % reduction in the TAT (15.65 days to 8.775 days). We also achieved a 30 % reduction in cost.
Conclusion
This is a prototype study highlighting the utility of DP in the lean management of HER2/neu testing. The integration of DP in the referral process reduces the TAT and expenditure optimizing resource utilisation.
期刊介绍:
The Journal of Pathology Informatics (JPI) is an open access peer-reviewed journal dedicated to the advancement of pathology informatics. This is the official journal of the Association for Pathology Informatics (API). The journal aims to publish broadly about pathology informatics and freely disseminate all articles worldwide. This journal is of interest to pathologists, informaticians, academics, researchers, health IT specialists, information officers, IT staff, vendors, and anyone with an interest in informatics. We encourage submissions from anyone with an interest in the field of pathology informatics. We publish all types of papers related to pathology informatics including original research articles, technical notes, reviews, viewpoints, commentaries, editorials, symposia, meeting abstracts, book reviews, and correspondence to the editors. All submissions are subject to rigorous peer review by the well-regarded editorial board and by expert referees in appropriate specialties.